As such, CEA has been used as a molecular target of CAR-T-cells in the treatment of liver metastases of colorectal cancers (NCT02416466, NCT02850536, and NCT00004178) and for developing T-cell therapy (NCT01373047) as an ex vivo gene therapy. Here, CEACAM5 is linked to colorectal cancer.